share_log

Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report

Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report

報告指丹納赫有興趣收購加泰羅尼亞的價值顯著溢價
Benzinga Real-time News ·  2023/02/06 07:47
  • Danaher Corporation (NYSE:DHR) has reportedly expressed interest in acquiring the contract manufacturer Catalent Inc (NYSE:CTLT).
  • According to the sources, the recent moves by the life science firm valued Catalent at a significant premium.
  • It's unclear how Catalent will proceed or whether it's receptive to a takeover offer, Bloomberg reported citing people familiar with the matter.
  • Related: Danaher Says 2022 'Another Great Year,' Delivers Around 10% Core Revenue Growth.
  • Danaher and Catalent deal could be one of the largest transactions this year in a sleepy dealmaking market, with volumes down two-thirds globally, the report added.
  • "As a matter of company policy, Catalent does not comment on market rumors or speculation," the report cited a company spokesperson.
  • Also Read: Catalent-Repligen Merger 'Seems Unlikely,' This Analyst Says.
  • Last year, Catalent received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for Novo Nordisk A/S's (NYSE:NVO) obesity drug Wegovy.
  • Catalent provides delivery technologies and development solutions for drugs, biologics, and consumer health products. The manufacturer has gained distinction during the pandemic, helping to produce COVID-19 vaccines and treatments in partnership with companies including Moderna Inc (NASDAQ:MRNA), Johnson & Johnson (NYSE:JNJ), and AstraZeneca Plc (NASDAQ:AZN).
  • Price Action: CTLT shares are up 25.74% at $70.48 during the premarket session on the last check Monday.
  • 丹纳赫公司 據報，紐約證券交易所代號：DHR）表示有興趣收購合約製造商 加泰隆特公司 (紐約時間:CTLT).
  • 據消息人士透露，這家生命科學公司最近的舉動重視了 Catalent 的顯著溢價。
  • 目前尚不清楚 Catalent 將如何進行，或者它是否接受收購報價，彭博社報導引用了熟悉此事的人。
  • 相關： 達納赫稱 2022 年「又一個偉大的一年」實現了約 10% 的核心營收成長。
  • 該報告補充說，丹納赫（Danaher）和 Catalent 的交易可能是今年在昏昏欲睡的交易市場中最大的交易之一，全球交易量下降了三分之二。
  • 「作為公司政策問題，Catalent 沒有評論市場謠言或猜測，」該報告援引一位公司發言人。
  • 另請閱讀： 這位分析師稱，加泰羅尼亞-雷普利根合併「似乎不太可能」。
  • 去年，Catalent 因其在比利時的注射器填充設施而獲得了 FDA 的文章，「據稱」是供應短缺背後的罪魁禍首 諾和諾德A/S的A/S (紐約證券交易所代碼:NVO) 肥胖藥物韋戈維.
  • Catalent 為藥物，生物製劑和消費者保健品提供交付技術和開發解決方案。製造商在大流行期間獲得了卓越表現，幫助與包括以下公司合作生產 COVID-19 疫苗和治療方法 現代公司 (納斯達克:姆拉納), 強生 (紐約證券交易所代碼:JNJ)，以及 阿斯利康 (納斯達克:AZN).
  • 價格行動： 在上次檢查週一的上市前時段中，CTLT 股價上漲了 25.74％，價格為 70.48 美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論